Histone deacetylase inhibitors and rational combination therapies.
about
Oncolytic viruses as therapeutic cancer vaccinesHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with TemozolomidePersonalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma CellsRational Combinations of Targeted Agents in AMLThe Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with DoxorubicinPhase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasEpigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.Chromatin remodeling by polyamines and polyamine analogs.STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.Novel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3).AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.Targeting triple negative breast cancer with histone deacetylase inhibitors.HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.AP-1 confers resistance to anti-cancer therapy by activating XIAP.HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth and via inhibiting HDAC8 expression
P2860
Q21245758-E2C7CAA1-DCDC-4757-99B4-D6F299000778Q33983255-8971AF87-5578-4264-B592-4C2D8A77DBB8Q34318242-F1000545-FA9E-46ED-95C0-A33FB92D196CQ34664129-D34BFCED-B734-48F7-A41C-437BD70E3CB7Q35287823-38406415-1DE9-4776-861B-84FDF53E361DQ35636540-A435CA62-0674-48B5-B718-7BC810DBFFFCQ35750491-FA096BEF-3B12-4A38-A3E4-1D51529F4630Q35890561-AB3F4278-F2FB-466E-B4E0-3C2DF1410A7EQ36703448-C05479CA-300C-49D0-A610-C6139B0F1D76Q36853857-3A36F487-6C88-4A36-AE6E-A637B64D69C9Q38120212-9A4F0BFC-192E-4831-A87D-19ADC1E2FBDCQ38177821-5F6A2370-8E1E-4B55-BFCE-93DF0A22DCA6Q38765451-904A78D1-1E28-41A9-9E0B-A9E55CF1FA48Q38840351-984082E1-1E67-4CBA-A846-BB20EC39FA03Q41392087-36395761-B601-4017-8663-38A49516E61CQ42659391-71E3EC57-6E35-4F92-9B0C-D1FD16AC7C3BQ47836540-BAC8023A-6DDB-42EE-B72B-65C2330C33F6Q47927498-115B5B41-810D-4580-8912-59A501DC7C3DQ53669221-922FA21A-796B-4140-BF38-60AEFC22F1D4Q55478598-87B72594-0A09-4079-89AE-D9C0BAFF6942Q58572461-1DAA9A5F-2AA1-49B5-8710-55472EAE5738
P2860
Histone deacetylase inhibitors and rational combination therapies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Histone deacetylase inhibitors and rational combination therapies.
@en
type
label
Histone deacetylase inhibitors and rational combination therapies.
@en
prefLabel
Histone deacetylase inhibitors and rational combination therapies.
@en
P1476
Histone deacetylase inhibitors and rational combination therapies.
@en
P2093
P304
P356
10.1016/B978-0-12-394387-3.00006-9
P577
2012-01-01T00:00:00Z